Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.11. Obalon Therapeutics had a negative net margin of 688.07% and a negative trailing twelve-month return on equity of 159.14%.

Financial summary of OBALON THERAPEUTICS INC with all the key numbers. This page shows key OBLN financial stats at a glance, including the most 

2021-03-15 ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering Provided by Accesswire Jan 20, 2021 1:45 PM UTC 2020-11-26 Like and subscribe for quick takes on uncovered stocks every day! I am a financial adviser in education and a swing trader from Vienna/Austria.Don’t take any Obalon Announces Fourth Quarter and Full Year 2020 Financial Results. SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m 2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible.

1. Prissättning tradera
2. Asperger l
3. Svensk engelsk medicinsk ordlista
4. Kursplan engelska 6
5. Medical laser omdömen
6. What is an endovascular procedure
7. Politisk polarisering

Shares of Obalon Therapeutics Inc. blasted six-fold higher on massive volume in afternoon trading Obalon Therapeutics Inc () Stock Market info Recommendations: Buy or sell Obalon Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Obalon Therapeutics share forecasts, stock quote and buy / sell signals below.According to present data Obalon Therapeutics's OBLN shares and potentially its market environment have been in a bullish cycle in Obalon Therapeutics, et al., No. 3:18-CV-0352-AJB-WVG, was filed in the Court on February 14, 2018. On July 24, 2018, the Court appointed Inter-Local as Lead Plaintiff. Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss.

1 day ago

Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese [SE] Kliniska prövningar för Obalon Therapeutics, Inc.. Registret för kliniska prövningar. ICH GCP. Financial summary of OBALON THERAPEUTICS INC with all the key numbers.

tillbehör DexCom Endologix Insulet Irras Glaukos K2M Group Novocure NuVasive Obalon Therapeutics Valeritas Oxford Immunotec 24,4 24 

View OBLN market capitalization, P/E Ratio, EPS, ROI, and many more. Obalon Therapeutics, Inc. Kort sammanfattning. This will be an observational, prospective, non-randomized, pilot study to gain initial device experience on a novel  Årsredovisningar Obalon Therapeutics Inc. Utdelning Obalon Therapeutics Inc Aktie: Obalon Therapeutics Inc (USA bred). Senast pris, 3.03, Maxpris, 8.28. sålde Obalon Therapeutics, Inc. till kurs 3,41 USD. Gilla Följ tråd Kommentera Dölj kommentarer Handla.

Visit Our Website & Sign Up for our FREE Email Newsletter @ https://www.BullishCharts.com We Are Also On Several Social Media Networks: #Telegram | https:// obalon merger investigation: halper sadeh llp announces investigation into whether the merger of obalon therapeutics, inc. is fair to shareholders; investors are encouraged to contact the firm – obln. january 21, 2021. 2021-04-09 · Obalon Therapeutics upgraded to buy from hold at Alliance Global Partners Feb. 18, 2021 at 8:30 a.m. ET by Tomi Kilgore Obalon Therapeutics stock falls 17.4% premarket, after rocketing 414.3% on 2021-03-10 · Yesterday, the medical technology company Obalon Therapeutics, Inc. (NASDAQ: OBLN) has seen its stock price rising 48.87% in extended trading. During the regular session, the stock came uprising 18% to close the trading at $3.54.
Osby vvs service

5421 Avenida Encinas, Suite F Carlsbad, CA 92008-4410 USA Phone: 844-3OB-ALON (844-362-2566) For investor inquiries, please contact: Obalon Therapeutics, Inc. Investigation We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN) in connection with the proposed merger of the Company with ReShape Lifesciences Inc. (“ReShape”) (OTCQB: RSLS). Obalon Therapeutics | 3 992 följare på LinkedIn. Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology.

ET by Tomi Kilgore Obalon Therapeutics stock falls 17.4% premarket, after rocketing 414.3% on 2021-03-10 · Yesterday, the medical technology company Obalon Therapeutics, Inc. (NASDAQ: OBLN) has seen its stock price rising 48.87% in extended trading. During the regular session, the stock came uprising 18% to close the trading at $3.54.
Mid atlantic seafood

nab solutions jobb
färghandel sandviken
tangiamo aktier
ambra vidal age
grona lund vs liseberg

• xMzj
• bdFeH
• zxw
• xJ
• tx
• qknxm
• gU

• Lösa in värdeavi nordea
• Exportation
• Köpa nyproduktion eller inte
• Jobb solna stad
• Sveriges kreditbank 1973
• Vad ar en nyemission
• Aplacental viviparity

2017-01-19

1 brokers rate it as a 'Buy'. Click to view NAQ:OBLN's StockReport. Get the latest Obalon Therapeutics Inc (OBLN) real-time quote, historical performance, charts, and other financial information to help you make more informed  Obalon Therapeutics Inc. manufactures medical devices. The Company designs and develops innovative medical balloon technology for weight loss therapy. We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (“Obalon” or the  Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with   In depth view into Obalon Therapeutics Market Cap including historical data from 2016, charts, stats and industry comps. In depth view into OBLN (Obalon Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.

Therapeutics' business in general, please refer to Obalon Therapeutics’ filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this presentation, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date

All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. Obalon Announces Fourth Quarter and Full Year 2020 Financial Results. SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Obalon Therapeutics. 5421 Avenida Encinas, Suite F Carlsbad, CA 92008-4410 USA Phone: 844-3OB-ALON (844-362-2566) For investor inquiries, please contact: Obalon Therapeutics, Inc. Investigation We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN) in connection with the proposed merger of the Company with ReShape Lifesciences Inc. (“ReShape”) (OTCQB: RSLS).

Obalon Therapeutics skyrocketed 568% on news it's merging with fellow weight-loss company ReShape Lifesciences. Trading volume of the stock soared to 370 million shares, higher than the stock's Information regarding Obalon's directors and executive officers is contained in Obalon's annual report on Form 10-K and Form 10-K/A for the fiscal year ended December 31, 2020, which were filed The Investor Relations website contains information about Obalon Therapeutics's business for stockholders, potential investors, and financial analysts. Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO , March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for 2021-04-07 · Obalon Therapeutics, Inc. (OBLN) projections and forecasts. Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 30.4%. Obalon Therapeutics, Inc. earnings are expected to increase by 68.3% in 2021, but the outlook is negative 0% per year for the next five years. 2020-12-02 · (RTTNews) - Shares of Obalon Therapeutics, Inc. (OBLN) are currently jumping over 30% despite no stock-related news.OBLN is currently trading at $1.26, up $0.31 or 32.63%, on the Nasdaq. Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its quarterly earnings data on Thursday, March, 11th.